ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0021094

immunodeficiency disease

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. immunodeficiency disease. Diseases, record MONDO_0021094. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021094

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
immunodeficiency disease
Open Targets
Open Targets ID
MONDO_0021094
Open Targets
Other names
Decreased immune function, Immune deficiency, Other immunodeficiency syndrome due to defects in adaptive immunity, immuno-deficiency, immunodeficiency, immunodeficiency disorder
Open Targets
NCI Thesaurus
C3131
NCI Thesaurus
Highest stage of its drugs
Approval, for 11 of its 33 drugs, from DailyMed and TTD
Open Targets

Drugs33

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
HUMAN IMMUNOGLOBULIN GCHEMBL1201599ApprovalTTD420Drugs and targets
LAMIVUDINECHEMBL141Small moleculeApprovalDailyMed700Drugs and targets
ABACAVIR SULFATECHEMBL4303288Small moleculeApprovalDailyMed400Drugs and targets
ZIDOVUDINECHEMBL129Small moleculeApprovalDailyMed300Drugs and targets
RALTEGRAVIR POTASSIUMCHEMBL518520Small moleculeApprovalDailyMed200Drugs and targets
DARUNAVIR ETHANOLATECHEMBL1201127Small moleculeApprovalDailyMed100Drugs and targets
DOLUTEGRAVIR SODIUMCHEMBL1213165Small moleculeApprovalDailyMed100Drugs and targets
EFAVIRENZCHEMBL223228Small moleculeApprovalDailyMed100Drugs and targets
FAMCICLOVIRCHEMBL880Small moleculeApprovalDailyMed100Drugs and targets
FOSAMPRENAVIR CALCIUMCHEMBL1200734Small moleculeApprovalDailyMed100Drugs and targets

1 to 10 of 33

See all 33 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
CSF3RGranulocyte colony-stimulating factor receptor3Granulocyte colony stimulating factor receptor agonistPhase 2/3https://conductscience.org/library/genes/1441Drugs and targets
PIK3CDPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform2PI3-kinase p110-delta subunit inhibitorPhase 2/3https://conductscience.org/library/genes/5293Drugs and targets
RRM1Ribonucleoside-diphosphate reductase RR12Ribonucleoside-diphosphate reductase RR1 inhibitorPhase 2https://conductscience.org/library/genes/6240Drugs and targets
RRM2Ribonucleoside-diphosphate reductase RR12Ribonucleoside-diphosphate reductase RR1 inhibitorPhase 2https://conductscience.org/library/genes/6241Drugs and targets
RRM2BRibonucleoside-diphosphate reductase RR12Ribonucleoside-diphosphate reductase RR1 inhibitorPhase 2https://conductscience.org/library/genes/50484Drugs and targets
ADORA1Adenosine receptor1Adenosine receptor agonistPhase 1/2https://conductscience.org/library/genes/134Drugs and targets
ADORA2AAdenosine receptor1Adenosine receptor agonistPhase 1/2https://conductscience.org/library/genes/135Drugs and targets
ADORA2BAdenosine receptor1Adenosine receptor agonistPhase 1/2https://conductscience.org/library/genes/136Drugs and targets
ADORA3Adenosine receptor1Adenosine receptor agonistPhase 1/2https://conductscience.org/library/genes/140Drugs and targets
CD52CAMPATH-1 antigen1CAMPATH-1 antigen inhibitorPhase 2/3https://conductscience.org/library/genes/1043Drugs and targets

1 to 10 of 28

See all 28 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00071890
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
Phase 21482010-10-05HIV InfectionsALDESLEUKINIts record names the diseaseClinicalTrials.gov
NCT01704781Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)Phase 1/2362017-03-08HIV-1 InfectionLENALIDOMIDEIts record names the diseaseClinicalTrials.gov
NCT00176826T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersPhase 2/3222014-04-28Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Diseases, Langerhans-Cell Histiocytosis, Hematologic DiseasesBUSULFAN, CYCLOPHOSPHAMIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT02512679Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood CellsPhase 2202016-06-17
Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Transplantation, Genetic Diseases, Thalassemia, Pediatrics, Diamond-Blackfan Anemia, Combined Immune Deficiency, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Lymphoproliferative Disease, Metabolic Diseases
ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINEOpen Targets' reading of its recordClinicalTrials.gov
NCT00923364Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMACPhase 2192017-11-30MDS, Immunodeficiency, GATA2ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE), CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINEIts record names the diseaseClinicalTrials.gov
NCT01962415Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTPhase 2100
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
ALEMTUZUMAB, FLUDARABINE, HYDROXYUREA, MELPHALAN, THIOTEPAOpen Targets' reading of its recordClinicalTrials.gov
NCT01019876Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesPhase 2/338Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined ImmunodeficiencyALEMTUZUMAB, BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINEOpen Targets' reading of its recordClinicalTrials.gov
NCT02859727Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLIPhase 2/337Activated PI3Kdelta Syndrome (APDS); PASLI DiseaseLENIOLISIB, LENIOLISIB PHOSPHATEIts record names the diseaseClinicalTrials.gov
NCT00295971Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseasePhase 121Congenital Amegakaryocytic Thrombocytopenia, Leukemia, Myelodysplastic Syndromes, Severe Congenital NeutropeniaFLUDARABINE PHOSPHATE, THIOTEPAIts record names the diseaseClinicalTrials.gov
NCT06324877Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide RibosideNot applicable10Ataxia TelangiectasiaNICOTINAMIDE RIBOSIDEIts record names the diseaseClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
32750127RESULT1PubMed
25459642RESULT1PubMed
21816832RESULT1PubMed
40739200DERIVED1PubMed
38819800DERIVED1PubMed
38593221DERIVED1PubMed
37797893DERIVED1PubMed
32634238DERIVED1PubMed
24077845DERIVED1PubMed
23344397DERIVED1PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021094

GET https://conductscience.org/api/diseases/v1/MONDO_0021094/drugs?page=2

API referenceFor AI assistants